Newsletter | April 20, 2026

04.20.26 -- From IV To Subcutaneous: Patients Weigh In On The Why

SPONSOR

 

 

Join Drug Delivery Live Chief Editor Tom von Gunden on April 23 at 11am eastern for the virtual event: Just Breathe: Increasing Efficacy And Expanding Targets With Inhalation Delivery. This panel discussion will illuminate ways in which innovations in inhalation, via both oral and nasal routes to respiratory pathways and the lungs, are increasing patient convenience and therapeutic efficacy while expanding the range of targeted indications. Registration is free.

FEATURED EDITORIAL

From IV To Subcutaneous: Patients Weigh In On The Why

In this episode of In Combination, patients Todd Kennedy and Cathleen Bergin describe for videocast host Tom von Gunden the significant life and health transformations brought about when their treatment regimens shifted from IV to subcutaneous administration. Adding perspective on the technology enablers is Chief Medical Officer Charles Theuer from drug delivery systems provider Halozyme. 

 

Electronic Drug Delivery Devices: Advancing Smart, Connected Healthcare

What is factoring into market growth for electronic drug delivery devices and why? New market research shares key insights.

INDUSTRY INSIGHTS

 

Drug Delivery Device Manufacturing

Biologics and targeted therapies unlock new device innovation—but low annual volumes demand smart manufacturing strategies that still deliver commercial viability.

 

Scaling Custom Activated PEGs With CDMO Support

Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

 

Powering Next Generation Active Implants

Active implants are pushing past battery limits as energy‑harvesting taps motion, heat, and biochemical signals. Hybrid systems could shrink devices and enable longer‑lasting, self‑powered implants.

 

Using High-Content Imaging To Accelerate Molecule Selection

Delve into our cost-effective high-content immunofluorescence workflow using this system to efficiently identify small molecule protein degraders with rich, multi-dimensional data.

SOLUTIONS

De-Risk Your Combination Product Development

Selecting A CDMO: A Guide To Successful Collaboration